Untangling the Interplay of Genetic and Metabolic Influences on Beta-cell Function: Examples of Potential Therapeutic Implications Involving TCF7L2 and FFAR1

Overview

Journal Mol Metab

Specialty Cell Biology

Date 2014 Apr 22

PMID 24749055

Citations 9

Authors

Robert Wagner

Harald Staiger

Susanne Ullrich

Norbert Stefan

Andreas Fritsche

Hans-Ulrich Haring

Affiliations

Soon will be listed here.

Abstract

Deteriorating beta-cell function is a common feature of type 2 diabetes. In this review, we briefly address the regulation of beta-cell function, and discuss some of the main determinants of beta-cell failure. We will focus on the role of interactions between the genetic background and metabolic environment (insulin resistance, fuel supply and flux as well as metabolic signaling). We present data on the function of the strongest common diabetes risk variant, the single nucleotide polymorphism (SNP) rs7903146 in TCF7L2. As also mirrored by its interaction with glycemia on insulin secretion, this SNP in large part confers resistance against the incretin effect. Genetic influence on insulin secretion also interacts with free fatty acids, as evidenced by data on rs1573611 in FFAR1. Several medications marketed by now or currently under development for diabetes treatment engage these pathways, and therapeutic implications from these findings are soon to be expected.

Citing Articles

Nutrigenomics in Regulating the Expression of Genes Related to Type 2 Diabetes Mellitus.

Felisbino K, Granzotti J, Bello-Santos L, Guiloski I Front Physiol. 2021; 12:699220.

PMID: 34366888 PMC: 8334860. DOI: 10.3389/fphys.2021.699220.

Pancreatic Steatosis Associates With Impaired Insulin Secretion in Genetically Predisposed Individuals.

Wagner R, Jaghutriz B, Gerst F, Oquendo M, Machann J, Schick F J Clin Endocrinol Metab. 2020; 105(11).

PMID: 32725157 PMC: 7497818. DOI: 10.1210/clinem/dgaa435.

Gene x Gene Interactions Highlight the Role of Incretin Resistance for Insulin Secretion.

Jaghutriz B, Heni M, Lutz S, Fritsche L, Machicao F, Staiger H Front Endocrinol (Lausanne). 2019; 10:72.

PMID: 30846969 PMC: 6393347. DOI: 10.3389/fendo.2019.00072.

Excessive fuel availability amplifies the FTO-mediated obesity risk: results from the TUEF and Whitehall II studies.

Wagner R, Tabak A, Fehlert E, Fritsche L, Jaghutriz B, Banhegyi R Sci Rep. 2017; 7(1):15486.

PMID: 29138452 PMC: 5686126. DOI: 10.1038/s41598-017-15744-4.

Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials.

Shomali M, Orsted D, Cannon A Diabet Med. 2016; 34(2):197-203.

PMID: 27412701 PMC: 5248619. DOI: 10.1111/dme.13185.

References

Poitout V, Robertson R . Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev. 2007; 29(3):351-66. PMC: 2528858. DOI: 10.1210/er.2007-0023. View

Zhang C, Katoh M, Shibasaki T, Minami K, Sunaga Y, Takahashi H . The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science. 2009; 325(5940):607-10. DOI: 10.1126/science.1172256. View

Florez J, Jablonski K, Bayley N, Pollin T, de Bakker P, Shuldiner A . TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med. 2006; 355(3):241-50. PMC: 1762036. DOI: 10.1056/NEJMoa062418. View

Poitout V, Lin D . Modulating GPR40: therapeutic promise and potential in diabetes. Drug Discov Today. 2013; 18(23-24):1301-8. DOI: 10.1016/j.drudis.2013.09.003. View

da Silva Xavier G, Loder M, McDonald A, Tarasov A, Carzaniga R, Kronenberger K . TCF7L2 regulates late events in insulin secretion from pancreatic islet beta-cells. Diabetes. 2009; 58(4):894-905. PMC: 2661588. DOI: 10.2337/db08-1187. View

Meier J, Nauck M . Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?. Diabetes. 2010; 59(5):1117-25. PMC: 2857890. DOI: 10.2337/db09-1899. View

Lan H, Hoos L, Liu L, Tetzloff G, Hu W, Abbondanzo S . Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes. 2008; 57(11):2999-3006. PMC: 2570396. DOI: 10.2337/db08-0596. View

Mussig K, Staiger H, Machicao F, Haring H, Fritsche A . Genetic variants affecting incretin sensitivity and incretin secretion. Diabetologia. 2010; 53(11):2289-97. DOI: 10.1007/s00125-010-1876-8. View

Prentki M, Matschinsky F, Murthy Madiraju S . Metabolic signaling in fuel-induced insulin secretion. Cell Metab. 2013; 18(2):162-85. DOI: 10.1016/j.cmet.2013.05.018. View

10.

Aschard H, Chen J, Cornelis M, Chibnik L, Karlson E, Kraft P . Inclusion of gene-gene and gene-environment interactions unlikely to dramatically improve risk prediction for complex diseases. Am J Hum Genet. 2012; 90(6):962-72. PMC: 3370279. DOI: 10.1016/j.ajhg.2012.04.017. View

11.

Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L . The many faces of diabetes: a disease with increasing heterogeneity. Lancet. 2013; 383(9922):1084-94. DOI: 10.1016/S0140-6736(13)62219-9. View

12.

Zheng J, Arnett D, Lee Y, Shen J, Parnell L, Smith C . Genome-wide contribution of genotype by environment interaction to variation of diabetes-related traits. PLoS One. 2013; 8(10):e77442. PMC: 3810463. DOI: 10.1371/journal.pone.0077442. View

13.

Heni M, Ketterer C, Thamer C, Herzberg-Schafer S, Guthoff M, Stefan N . Glycemia determines the effect of type 2 diabetes risk genes on insulin secretion. Diabetes. 2010; 59(12):3247-52. PMC: 2992789. DOI: 10.2337/db10-0674. View

14.

Schulze M, Weikert C, Pischon T, Bergmann M, Al-Hasani H, Schleicher E . Use of multiple metabolic and genetic markers to improve the prediction of type 2 diabetes: the EPIC-Potsdam Study. Diabetes Care. 2009; 32(11):2116-9. PMC: 2768223. DOI: 10.2337/dc09-0197. View

15.

Schafer S, Mussig K, Staiger H, Machicao F, Stefan N, Gallwitz B . A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion. Diabetologia. 2009; 52(6):1075-82. DOI: 10.1007/s00125-009-1344-5. View

16.

Eitel K, Staiger H, Rieger J, Mischak H, Brandhorst H, Brendel M . Protein kinase C delta activation and translocation to the nucleus are required for fatty acid-induced apoptosis of insulin-secreting cells. Diabetes. 2003; 52(4):991-7. DOI: 10.2337/diabetes.52.4.991. View

17.

Fisher E, Boeing H, Fritsche A, Doering F, Joost H, Schulze M . Whole-grain consumption and transcription factor-7-like 2 ( TCF7L2) rs7903146: gene-diet interaction in modulating type 2 diabetes risk. Br J Nutr. 2009; 101(4):478-81. DOI: 10.1017/S0007114508020369. View

18.

Zeggini E, Scott L, Saxena R, Voight B, Marchini J, Hu T . Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet. 2008; 40(5):638-45. PMC: 2672416. DOI: 10.1038/ng.120. View

19.

Boj S, van Es J, Huch M, Li V, Jose A, Hatzis P . Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. Cell. 2012; 151(7):1595-607. DOI: 10.1016/j.cell.2012.10.053. View

20.

Holstein A, Hahn M, Korner A, Stumvoll M, Kovacs P . TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Med Genet. 2011; 12:30. PMC: 3051886. DOI: 10.1186/1471-2350-12-30. View